• Hanna I Hyry, Timothy M Cox, and Roos Jonathan C P JC a Department of Medicine , University of Cambridge , Cambridge , United Kingdom..
• a Department of Medicine , University of Cambridge , Cambridge , United Kingdom.
• Expert Rev Pharmacoecon Outcomes Res. 2016 Jan 1; 16 (1): 111-7.

AbstractOrphan-drug sales are rocketing, with revenue expected to total $176 billion annually by 2020. As a share of the industry, orphan drugs now account for close to 15% of all prescription revenue globally (excluding generics) and the sector is set to grow at more than twice the rate (10.5%) of the overall prescription market (4.3%). But this success also equates to costs--borne by individual patients and cash-strapped health systems. Prices for orphan drugs can be 19 times higher than for other medications, hampering access for patients, many of whom are children. With ever more such expensive drugs reaching the market, the situation is becoming unsustainable and putting the survival of the orphan drug legislation itself at risk. Here the authors consider why there has been an increase in orphan drug designations, how orphan drug prices are set and regulated, before discussing proposals for how changes which could save the legislation.

18 keywords...

hide…